![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of Cabotegravir + Rilpivirine (LATTE-2) in the United States and Spain
|
|
|
Reported by Jules Levin
Durban 2016 July 18-22
Deanna Kerrigan1, Andrea Mantsios1, David Margolis2, Miranda Murray2
1Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
2ViiV Healthcare, Research Triangle Park, USA & London, UK
![IAC1](../images/072516/072516-7/IAC1.gif)
![IAC2](../images/072516/072516-7/IAC2.gif)
![IAC3](../images/072516/072516-7/IAC3.gif)
![IAC4](../images/072516/072516-7/IAC4.gif)
![IAC5](../images/072516/072516-7/IAC5.gif)
![IAC6](../images/072516/072516-7/IAC6.gif)
![IAC7](../images/072516/072516-7/IAC7.gif)
![IAC8](../images/072516/072516-7/IAC8.gif)
![IAC9](../images/072516/072516-7/IAC9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|